Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hemophilia B Gene Therapy - Spark

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Children's Hospital of Philadelphia
University of Pittsburgh
Royal Prince Alfred Hospital, Sydney, Australia
St. James's Hospital, Ireland
Information provided by (Responsible Party):
Spark Therapeutics
ClinicalTrials.gov Identifier:
NCT01620801
First received: June 12, 2012
Last updated: May 18, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2029
  Estimated Primary Completion Date: October 2019 (Final data collection date for primary outcome measure)